Variants in the ITPKC gene affect the efficacy of intravenous immunoglobulin (IVIG) treatment in patients with Kawasaki disease, with certain polymorphisms leading to reduced responsiveness. This pharmacodynamic interaction emphasizes the need to consider ITPKC gene variations to predict and optimize IVIG therapy outcomes in treating Kawasaki disease.